Navigation Links
Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201,(Archexin) to Be Presented at the 43rd American Society of Clinical,Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.

The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit www.rexahn.com.

Contact

Rexahn Pharmaceuticals, Inc.
Amanda Sawney, 240-268-5300 x300


'"/>




Page: 1

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... 2017  Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited to host ... at the Bonaventure Resort & Spa in Weston, Florida ... Luncheon ... Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a ... Missouri. The company has achieved record-breaking sales for over 30 consecutive years and ... 12 months. , The upcoming year offers excitement and growth at HDIS, following the ...
(Date:7/25/2017)... PALM SPRINGS, California (PRWEB) , ... July 25, 2017 , ... ... don't involve cranking up the air conditioner — think homemade gourmet ice cream, sparkling ... up inside a gift shop featuring fun mugs, journals, and other must-have knick knacks. ...
(Date:7/25/2017)... Deerfield Beach, Florida (PRWEB) , ... July 25, ... ... newest employee, Jennifer Haller, to the sales department joining as Regional Account Manager ... maintain relationships with contracted customers in the liquidation of their obsolete medical assets. ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist ... partnership to provide the Pharmacist eCare Plan to Computer-Rx pharmacies through ... with the ability to develop the Pharmacist eCare Plan, a shared document detailing ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance Group, a ... communities across North Carolina, is launching a charity event in conjunction with the ... the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy Network (BCAN) ...
Breaking Medicine News(10 mins):